Medicare AdvantageCoverageMedium impact
MA08.124e, Cemiplimab-rwlc (Libtayo®)
Independence Blue Cross·Oncology, Dermatology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.124e for Cemiplimab-rwlc (Libtayo®) has been updated with changes to medical necessity criteria, medical coding requirements, and general guidelines. This affects billing and coverage for this oncology medication used primarily for certain skin cancers.
Action Required
By December 29, 2025: Billing team must review updated medical necessity criteria and coding requirements for Cemiplimab-rwlc (Libtayo®) claims. Update prior authorization processes and documentation requirements for Medicare Advantage patients receiving this oncology drug. Ensure providers are aware of new guidelines to prevent claim denials.